Health Economics and Outcomes Research

Chemotherapy drug waste from single-dose vials increased 3-year incremental budget costs by over $100 million in Canada, but is not being modeled uniformly in economic evaluations.
Navigating Cancer’s triage software with the inclusion of symptom management pathways for cancer treatments has saved cancer care providers $3.4 million annually.
More than 23% of patients with breast cancer who undergo breast-conserving surgery followed by subsequent surgery do not receive the full benefits of surgery due to added costs and complications.
A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma.
Four leading national cancer organizations recently issued a joint position statement in order to help guide the future of cancer health disparities research.
Researchers identified which imaging technique is better for evaluating prognosis of newly-diagnosed multiple myeloma.
Intensified regimens improve event-free survival and overall survival in patients newly diagnosed with diffuse large B-cell lymphoma compared with standard therapy.
A recent analysis reports a cost-effective alternative modality that demonstrates similar efficacy to traditional breast MRI.
Patients with diffuse large B-cell lymphoma benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy.